Capricor Therapeutics (CAPR) Short Interest Ratio & Short Volume $7.70 -0.26 (-3.27%) Closing price 04:00 PM EasternExtended Trading$7.78 +0.08 (+0.97%) As of 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Capricor Therapeutics Short Interest DataCapricor Therapeutics (CAPR) has a short interest of 11.11 million shares, representing 27.18% of the float (the number of shares available for trading by the public). This marks a 13.37% increase in short interest from the previous month. The short interest ratio (days to cover) is 3.9, indicating that it would take 3.9 days of the average trading volume of 2.02 million shares to cover all short positions.Current Short Interest11,110,000 sharesPrevious Short Interest9,800,000 sharesChange Vs. Previous Month+13.37%Dollar Volume Sold Short$90.88 millionShort Interest Ratio3.9 Days to CoverLast Record DateJuly 31, 2025Outstanding Shares45,720,000 sharesShort Percent of Float27.18%Today's Trading Volume1,185,561 sharesAverage Trading Volume2,020,830 sharesToday's Volume Vs. Average59% Short Selling Capricor Therapeutics? Sign up to receive the latest short interest report for Capricor Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCAPR Short Interest Over TimeCAPR Days to Cover Over TimeCAPR Percentage of Float Shorted Over Time Capricor Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/202511,110,000 shares $90.88 million +13.4%27.2%3.9 $8.18 7/15/20259,800,000 shares $70.36 million -12.3%N/A3.3 $7.18 6/30/202511,170,000 shares $110.92 million +9.4%27.3%4.4 $9.93 6/15/202510,210,000 shares $120.27 million -7.9%25.0%4 $11.78 5/31/202511,080,000 shares $110.80 million -19.6%27.7%5.3 $10.00 5/15/202513,780,000 shares $131.74 million +33.3%34.4%6.7 $9.56 4/30/202510,340,000 shares $131.32 million -3.1%N/A6.1 $12.70 4/15/202510,670,000 shares $104.78 million +14.7%26.7%8 $9.82 3/31/20259,300,000 shares $88.26 million +2.5%23.2%7.5 $9.49 3/15/20259,070,000 shares $120.00 million +11.0%22.7%7.6 $13.23 Get the Latest News and Ratings for CAPR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/28/20258,170,000 shares $125.65 million +0.1%20.4%6.6 $15.38 2/15/20258,160,000 shares $130.15 million +6.4%20.4%6.9 $15.95 1/31/20257,670,000 shares $115.36 million +1.1%N/A6.5 $15.04 1/15/20257,590,000 shares $102.24 million -4.5%N/A6.1 $13.47 12/31/20247,950,000 shares $109.71 million +42.2%N/A4.8 $13.80 12/15/20245,590,000 shares $74.12 million +26.8%N/A1.6 $13.26 11/30/20244,410,000 shares $83.83 million +14.6%N/A1.3 $19.01 11/15/20243,850,000 shares $71.65 million -27.1%N/A1.2 $18.61 10/31/20245,280,000 shares $106.13 million -14.6%N/A1.8 $20.10 10/15/20246,180,000 shares $133.49 million +17.9%N/A2.1 $21.60 9/30/20245,240,000 shares $79.70 million -30.4%N/A2.1 $15.21 9/15/20247,530,000 shares $34.56 million +0.8%N/A8.5 $4.59 8/31/20247,470,000 shares $34.14 million +6.7%N/A19.5 $4.57 8/15/20247,000,000 shares $27.30 million +12.7%N/A16.5 $3.90 7/31/20246,210,000 shares $25.21 million +5.8%N/A14.4 $4.06 7/15/20245,870,000 shares $27.35 million +25.7%N/A13.6 $4.66 6/30/20244,670,000 shares $22.28 million +3.6%N/A10.8 $4.77 6/15/20244,510,000 shares $23.32 million -1.3%N/A12.6 $5.17 5/31/20244,570,000 shares $25.96 million +8.6%N/A12 $5.68 5/15/20244,210,000 shares $22.44 million +1.7%N/A11.6 $5.33 4/30/20244,140,000 shares $21.82 million +15.3%N/A12.8 $5.27 4/15/20243,590,000 shares $21.04 million +2.6%N/A12 $5.86 3/31/20243,500,000 shares $23.77 million +8.4%N/A13 $6.79 3/15/20243,230,000 shares $20.64 million +19.6%N/A11.8 $6.39 2/29/20242,700,000 shares $11.34 million +0.8%N/A10.3 $4.20 2/15/20242,680,000 shares $10.10 million -0.4%N/A11.5 $3.77 1/31/20242,690,000 shares $10.87 million No ChangeN/A11.2 $4.04 1/15/20242,690,000 shares $11.89 million +14.5%N/A11 $4.42 12/31/20232,350,000 shares $11.49 million +10.3%N/A9.6 $4.89 12/15/20232,130,000 shares $9.24 million +45.9%N/A7.2 $4.34When the levee breaks (Ad)The U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.Click here to watch the urgent broadcast and get ahead of what’s coming. 11/30/20231,460,000 shares $4.34 million +7.4%N/A5.8 $2.97 11/15/20231,360,000 shares $4.37 million +10.6%N/A5.4 $3.21 10/31/20231,230,000 shares $3.47 million +1.7%N/A4.7 $2.82 10/15/20231,210,000 shares $3.46 million +80.8%N/A5 $2.86 9/30/2023669,100 shares $2.29 million +22.2%N/A3.2 $3.42 9/15/2023547,600 shares $3.43 million +36.4%N/A4.4 $6.26 8/31/2023401,500 shares $2.60 million +27.3%N/A3.2 $6.48 8/15/2023315,500 shares $2.25 million +14.0%N/A3.1 $7.14 7/31/2023276,700 shares $1.22 million +0.8%N/A3.7 $4.40 7/15/2023274,500 shares $1.23 million -0.3%N/A4 $4.48 6/30/2023275,200 shares $1.32 million +6.5%N/A3.7 $4.78 6/15/2023258,400 shares $1.24 million +0.8%N/A3.5 $4.80 5/31/2023256,300 shares $1.16 million -13.1%N/A3.8 $4.53 5/15/2023294,800 shares $1.24 million +11.0%N/A4.1 $4.19 4/30/2023265,700 shares $1.03 million +0.5%N/A3.5 $3.89 4/15/2023264,500 shares $1.16 million -3.8%N/A2.9 $4.38 3/31/2023274,800 shares $1.16 million -22.3%N/A2.9 $4.22 3/15/2023353,500 shares $1.58 million +4.5%N/A3.5 $4.47 2/28/2023338,200 shares $1.54 million +8.7%N/A3.3 $4.55 2/15/2023311,100 shares $1.25 million -5.2%N/A2.9 $4.03 1/31/2023328,300 shares $1.39 million -4.3%N/A2.8 $4.22 1/15/2023343,100 shares $1.50 million +0.7%N/A2.8 $4.38 12/30/2022340,900 shares $1.32 million +9.4%N/A2.5 $3.86 12/15/2022311,700 shares $1.21 million +30.8%N/A1.9 $3.89 11/30/2022238,400 shares $1.07 million -8.5%N/A1.4 $4.47 11/15/2022260,600 shares $1.06 million +5.3%N/A1.4 $4.09 10/31/2022247,500 shares $1.38 million -16.9%N/A1.2 $5.56 10/15/2022297,800 shares $1.74 million -10.0%N/A1.5 $5.83 9/30/2022330,900 shares $1.99 million +55.3%N/A1.7 $6.00 9/15/2022213,100 shares $1.25 million -25.5%N/A1.2 $5.87 8/31/2022286,100 shares $1.67 million -5.9%N/A1.7 $5.82 8/15/2022304,100 shares $1.49 million -15.2%N/A2.2 $4.89 7/31/2022358,500 shares $1.65 million -9.1%N/A3.2 $4.61 7/15/2022394,500 shares $1.99 million -9.6%N/A3.4 $5.05 6/30/2022436,600 shares $1.52 million -12.5%N/A3.8 $3.49 6/15/2022499,100 shares $2.05 million -2.7%2.5%3.1 $4.11 5/31/2022512,800 shares $1.86 million -8.6%N/A3 $3.63 5/15/2022561,000 shares $1.72 million -4.4%N/A3 $3.06 4/30/2022586,600 shares $1.86 million -9.2%N/A2.9 $3.17 4/15/2022645,800 shares $2.12 million -7.1%N/A1.7 $3.29 3/31/2022695,100 shares $2.38 million -3.2%N/A1.8 $3.43 3/15/2022718,300 shares $2.97 million -20.7%N/A2.1 $4.14 2/28/2022905,200 shares $3.67 million +4.1%N/A2.6 $4.05 2/15/2022869,900 shares $3.76 million -7.0%N/A2.5 $4.32 1/31/2022934,900 shares $3.34 million +69.6%N/A2.6 $3.57 1/15/2022551,200 shares $1.70 million -18.3%N/A1.9 $3.09 12/31/2021675,000 shares $1.98 million -13.7%N/A3.5 $2.93 12/15/2021781,900 shares $2.47 million -12.1%N/A1.2 $3.16 11/30/2021889,000 shares $3.00 million -2.5%N/A1.3 $3.37 11/15/2021912,000 shares $3.12 million +0.4%N/A1.4 $3.42When the levee breaks (Ad)The U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.Click here to watch the urgent broadcast and get ahead of what’s coming. 10/29/2021908,600 shares $3.38 million -11.8%4.0%1.4 $3.72 10/15/20211,030,000 shares $4.08 million -12.0%4.6%1.6 $3.96 9/30/20211,170,000 shares $4.70 million +60.5%5.2%1.7 $4.02 9/15/2021728,900 shares $3.24 million +8.6%3.2%1.1 $4.45 8/31/2021671,100 shares $3.36 million -10.3%3.0%1.9 $5.01 8/13/2021748,100 shares $3.02 million -30.7%3.3%2.2 $4.04 7/30/20211,080,000 shares $4.72 million -49.8%4.8%3 $4.37 7/15/20212,150,000 shares $9.31 million -4.9%9.6%3.9 $4.33 6/30/20212,260,000 shares $11.59 million +17.7%10.1%4.1 $5.13 6/15/20211,920,000 shares $8.70 million +10.3%8.6%3.6 $4.53 5/28/20211,740,000 shares $6.59 million -0.6%7.8%4.1 $3.79 5/14/20211,750,000 shares $5.53 million +53.5%N/A3.7 $3.16 4/30/20211,140,000 shares $5.18 million +30.7%N/A2.1 $4.54 4/15/2021872,200 shares $3.55 million -7.2%N/A1.4 $4.07 3/31/2021939,500 shares $4.34 million +116.8%N/A1 $4.62 3/15/2021433,400 shares $2.25 million +25.6%N/A0.4 $5.18 2/26/2021345,200 shares $2.12 million -29.4%N/A0.4 $6.14 2/12/2021489,100 shares $3.81 million -29.3%N/A0.5 $7.80 1/29/2021691,900 shares $4.41 million -9.5%N/A0.7 $6.38 1/15/2021764,800 shares $3.70 million +0.9%N/A0.9 $4.84 12/31/2020758,000 shares $2.80 million -0.9%N/A1.2 $3.70 12/15/2020765,000 shares $3.27 million -29.8%N/A1.6 $4.27 11/30/20201,090,000 shares $4.68 million -12.1%N/A1.5 $4.29 11/15/20201,240,000 shares $5.39 million +4.2%N/A1.4 $4.35 10/30/20201,190,000 shares $4.95 million -9.9%N/A1.2 $4.16 10/15/20201,320,000 shares $6.40 million -8.3%N/A0.6 $4.85 9/30/20201,440,000 shares $7.56 million -1.4%N/A0.5 $5.25 9/15/20201,460,000 shares $6.83 million -24.0%N/A0.5 $4.68 8/31/20201,920,000 shares $11.58 million -6.8%N/A0.7 $6.03 CAPR Short Interest - Frequently Asked Questions What is Capricor Therapeutics' current short interest? Short interest is the volume of Capricor Therapeutics shares that have been sold short but have not yet been closed out or covered. As of July 31st, investors have sold 11,110,000 shares of CAPR short. 27.18% of Capricor Therapeutics' shares are currently sold short. Learn More on Capricor Therapeutics' current short interest. What is a good short interest ratio for Capricor Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CAPR shares currently have a short interest ratio of 4.0. Learn More on Capricor Therapeutics's short interest ratio. Which institutional investors are shorting Capricor Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Capricor Therapeutics: Perceptive Advisors LLC, LMR Partners LLP, Group One Trading LLC, Boothbay Fund Management LLC, Bank of America Corp DE, Jane Street Group LLC, Caption Management LLC, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC , Diadema Partners LP, and Affinity Asset Advisors LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Capricor Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 27.18% of Capricor Therapeutics' floating shares are currently sold short. Is Capricor Therapeutics' short interest increasing or decreasing? Capricor Therapeutics saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 11,110,000 shares, an increase of 13.4% from the previous total of 9,800,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Capricor Therapeutics' short interest compare to its competitors? 27.18% of Capricor Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Capricor Therapeutics: Apogee Therapeutics Inc. (22.51%), Immunocore Holdings PLC Sponsored ADR (17.09%), Dyne Therapeutics, Inc. (13.35%), Cidara Therapeutics, Inc. (10.92%), Twist Bioscience Corporation (17.83%), Travere Therapeutics, Inc. (12.44%), Biohaven Ltd. (14.82%), Aurinia Pharmaceuticals Inc (7.88%), Schrodinger, Inc. (16.11%), Evotec AG (0.19%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), MicroStrategy Incorporated ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks. What does it mean to sell short Capricor Therapeutics stock? Short selling CAPR is an investing strategy that aims to generate trading profit from Capricor Therapeutics as its price is falling. CAPR shares are trading down $0.16 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Capricor Therapeutics? A short squeeze for Capricor Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CAPR, which in turn drives the price of the stock up even further. How often is Capricor Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CAPR, twice per month. The most recent reporting period available is July, 31 2025. More Short Interest Resources from MarketBeat Related Companies Apogee Therapeutics Short Squeeze Immunocore Short Squeeze Dyne Therapeutics Short Squeeze Cidara Therapeutics Short Squeeze Twist Bioscience Short Squeeze Travere Therapeutics Short Squeeze Biohaven Short Squeeze Aurinia Pharmaceuticals Short Squeeze Schrodinger Short Squeeze Evotec Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CAPR) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access